A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma
Esophageal Carcinoma
Conditions: official terms
Carcinoma - Carcinoma, Squamous Cell - Esophageal Neoplasms
Conditions: Keywords
Sodium Glycididazole, Radiochemotherapy, Esophageal Carcinoma
Study Type
Study Phase
Phase 4
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Name: placebo Type: Drug
Name: Sodium Glycididazole Type: Drug
Overall Status
This multicentered clinical trial is going to find out the radio-sensitization action of sodium glycididazole in radiochemotherapy for esophageal cancer.
Detailed Description
Esophageal cancer is one of the most frequent causes of cancer death in the world. The most common type of esophageal cancer is squamous cell carcinoma (SCC) in China. Although concurrent radiochemotherapy is recommended as the standard treatment for advanced esophageal carcinoma, the local failure still reaches up to 44%-54%.

Sodium Glycididazole(CMNa) is a radiosensitive drug for hypoxic tumor cells. Clinical trials showed that CMNa can improve local control rate and survival rate of esophageal cancer. This study is going to confirm the efficacy and safety of CMNa in concurrent radiochemotherapy of radiotherapy and 5-FU+DDP for esophageal squamous carcinoma.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- written informed consent

- photographically and histologically proven thoracic esophageal squamous carcinoma

- stages 2a-3, and stage 4 with only supraclavicular lymph nodes metastasis defined by AJCC(2002)

- radiochemotherapy indication

- measurable tumor

- adequate hematologic, hepatic and renal function

- Karnofsky performance status ≥70

- age more than 18years and less than 70 years

Exclusion Criteria:

- pregnancy and lactation

- significant neurologic disease

- severe liver and renal malfunction,and Significant medical illness

- previous chemotherapy, radiotherapy or immunotherapy

- esophagus hemorrhage and esophagus perforation features
Beijing Cancer Hospital
Beijing, Beijing, China
Status: Recruiting
Contact: Bo Xu, Doctor - 8610-88196170 - fangliaoxubo@vip.sina.com
Cancer Center of Sun Yat-sen University
Guangzhou, Guangdong, China
Status: Recruiting
Contact: Mengzhong Liu, Doctor - 8620-83743371 - lmz1955@163.com
Zhongshan Hospital of Fudan University
Shanghai, Shanghai, China
Status: Recruiting
Contact: Fengying Wang, Doctor - 8621-64160820
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Status: Recruiting
Contact: Lvhua Wang, Doctor - 86-10-87788503 - wlhwq@yahoo.com
Start Date
April 2008
Completion Date
December 2009
Shandong Luye Pharmaceutical Co., Ltd.
Shandong Luye Pharmaceutical Co., Ltd.
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page